Biocon introduces advanced therapy to treat Hepatitis C
Biotechnology major Biocon has launched advanced novel therapy for the treatment of Hepatitis C at low cost. CIMIVIR-L, a fixed dose combination of Ledipasvir 90 mg and Sofosbuvir 400 mg, will be made available to patients in India at a fraction of the global cost of the innovator brand. The cost of a 12-week course of this combination therapy in the US is USD 94,500 (about Rs 63 lakh). Biocon, President-Marketing, Ravi Limaye said the introduction of CIMIVIR-LTM will strengthen the company’s current portfolio of virology products.
CIMIVIR-L is an equivalent of the innovator product commercialised by Gilead Sciences in the US. Biocon had entered into a licensing agreement last year with US-based Gilead to manufacture and commercialise its chronic Hepatitis-C blockbuster product range, Sofosbuvir and Sofosbuvir-Ledipasvir combination in India and in select emerging markets. Read More